Kairos Pharma, LTD. filed a Form S-1 registration statement for an initial public offering on 2025-01-29. It has amended it 1 time. It filed its final prospectus on 2024-09-17, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on NYSE American under the symbol “KAPA.” On April 18, 2025, the last reported sale price of our common stock was $0.96 per share.From the S-1 filed 2025-04-22
Shares offered
This is a firm commitment initial public offering of shares of common stock, par value $0.001 per share, of Kairos Pharma, Ltd. We are offering 1,550,000 shares of our common stock at an initial public offering price of $4.00 per share.From the 424B4 filed 2024-09-17
Offering price
This is a firm commitment initial public offering of shares of common stock, par value $0.001 per share, of Kairos Pharma, Ltd. We are offering 1,550,000 shares of our common stock at an initial public offering price of $4.00 per share.From the 424B4 filed 2024-09-17
Use of proceeds
We intend to use the net proceeds obtained under the ELOC Agreement to fund Phase 1 and Phase 2 clinical trials of our product candidates, including ENV 105 and preclinical product candidates including KROS 101, potential acquisition or in-licensing activities, and working capital and general corporate purposes.From the S-1 filed 2025-04-22
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-16 | Registration statement amended | S-1/A |
| 2024-09-17 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-01-29 | Registration statement filed | S-1 |
| 2025-04-22 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for Kairos Pharma, LTD.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.